For the US, Canada and EU, the DrugBank team manually monitors new drug approvals and adds or updates existing DrugCard entries. New drug approvals and updates to existing product labels including indications, contraindications and pharmaceutical forms are tracked daily. Emergency use authorizations, withdrawals and the availability of new biosimilars are also tracked. Finally, for the US only, safety-related labelling changes (SrLCs), such as new adverse effects, boxed warnings and interactions are monitored. Once identified, these updates are passed to senior curators who review the updated product label and make any necessary changes. This daily tracking ensures that complete information for all approved drugs and drug products across all supported geographic regions are included within DrugBank in a timely manner.
